(Q45749050)

15 December 2017

title

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects (English)

1 reference

15 December 2017

1 reference

1 reference

1 reference

Matthias Hoch

1

1 reference

15 December 2017

Petra Hoever

2

1 reference

15 December 2017

Federica Alessi

3

1 reference

15 December 2017

Rudolf Theodor

4

1 reference

15 December 2017

Jasper Dingemanse

5

1 reference

15 December 2017

language of work or name

1 reference

19 September 2012

1 reference

15 December 2017

European Journal of Clinical Pharmacology

published in

1 reference

15 December 2017

volume

69

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

523-532

1 reference

15 December 2017

The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Orexins in the regulation of the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Statin safety and drug interactions: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Interaction between grapefruit juice and midazolam in humans*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

The effect of grapefruit juice on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Role of P-glycoprotein in statin drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1403-6

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

21 January 2018

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

Drug interactions due to cytochrome P450.

1 reference

12 December 2020

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase

1 reference

12 December 2020

10.1007/S00228-012-1403-6

Identifiers

DOI

1 reference

15 December 2017

Dimensions Publication ID

1045311764

0 references

1 reference

15 December 2017